Clinical Trial Update: Study of Erlotinib in Combination With Dasatinib [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of erlotinib and dasatinib in patients with advanced cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Sprycel (dasatinib)
• Tarceva (erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Cancer | Phase 1 | Status: COMPLETED